celecoxib has been researched along with Cancer of Ovary in 26 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of our study was to investigate the therapeutic potential of Celecoxib for epithelial ovarian cancer, especially on cellular morphological changes, proliferation invasion and epithelial-mesenchymal transition (EMT)." | 7.81 | Celecoxib induces epithelial-mesenchymal transition in epithelial ovarian cancer cells via regulating ZEB1 expression. ( Li, C; Liu, P; Liu, R; Pang, Y; Xu, X; Zheng, J; Zheng, Q, 2015) |
| "Celecoxib was to be continued after DC termination up to 3 years." | 6.77 | A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the Do ( de Graaf, H; de Munck, L; Erdkamp, FLG; Hoekman, K; Hollema, H; Lalisang, RI; Polee, M; Reyners, AKL; Schaapveld, M; Smit, WM; van Vugt, MATM; Willemse, PHB; Wymenga, ANM, 2012) |
| "However, the role of COX-2 in epithelial ovarian cancer (EOC), and its mechanistic details, remain poorly understood." | 5.48 | COX-2 inhibition by celecoxib in epithelial ovarian cancer attenuates E-cadherin suppression through reduced Snail nuclear translocation. ( Li, CH; Li, XW; Wang, QY; Wang, YP, 2018) |
| "The purpose of our study was to investigate the therapeutic potential of Celecoxib for epithelial ovarian cancer, especially on cellular morphological changes, proliferation invasion and epithelial-mesenchymal transition (EMT)." | 3.81 | Celecoxib induces epithelial-mesenchymal transition in epithelial ovarian cancer cells via regulating ZEB1 expression. ( Li, C; Liu, P; Liu, R; Pang, Y; Xu, X; Zheng, J; Zheng, Q, 2015) |
| "We first established the cytotoxicity of celecoxib in two COX-2-overexpressing E1A-transfected breast cancer cell lines (MDA-MB-231 and MDA-MB-435) and in two low-COX-2-expressing E1A-transfected cell lines (MCF-7 (breast cancer) and SKOV3." | 3.74 | Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells. ( Bartholomeusz, C; Sugimoto, T; Tari, AM; Ueno, NT, 2007) |
| "Celecoxib was to be continued after DC termination up to 3 years." | 2.77 | A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the Do ( de Graaf, H; de Munck, L; Erdkamp, FLG; Hoekman, K; Hollema, H; Lalisang, RI; Polee, M; Reyners, AKL; Schaapveld, M; Smit, WM; van Vugt, MATM; Willemse, PHB; Wymenga, ANM, 2012) |
| "No occult cases of ovarian cancer were identified and no differences in the presence of follicular cyst, hemorrhagic cysts, or inclusion cysts were noted on initial pathologic review." | 2.71 | Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: initial examination of celecoxib as a chemopreventive agent. ( Barnes, MN; Chhieng, DF; Dreher, M; Grizzle, WE; Jones, JL; Jones, L; Partridge, EE; Talley, L, 2005) |
| "Further, ovarian cancer cells with high expression of cyclooxygenase 2 exhibit enhanced proliferation and invasion abilities." | 1.51 | Cyclooxygenase 2 Promotes Proliferation and Invasion in Ovarian Cancer Cells via the PGE2/NF-κB Pathway. ( Deng, L; Feng, D; Liang, H; Liang, J; Ling, B; Yan, K; Zhang, X, 2019) |
| "However, the role of COX-2 in epithelial ovarian cancer (EOC), and its mechanistic details, remain poorly understood." | 1.48 | COX-2 inhibition by celecoxib in epithelial ovarian cancer attenuates E-cadherin suppression through reduced Snail nuclear translocation. ( Li, CH; Li, XW; Wang, QY; Wang, YP, 2018) |
| "DMBA-induced ovarian cancer in rats recapitulates many pathophysiological features of the human counterpart." | 1.48 | Preventative effect of celecoxib in dimethylbenz[a]anthracene-induced ovarian cancer in rats. ( Jiang, W; Kang, Y; Shao, Z; Wang, S; Wen, Q; Xu, C; Zhu, T, 2018) |
| "Treatment with celecoxib resulted in G1 cell cycle arrest, induction of apoptosis, inhibition of cellular adhesion and invasion and reduction of expression of hTERT mRNA and COX-2 protein in all of the ovarian cancer cell lines." | 1.43 | The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer. ( Bae-Jump, VL; Gehrig, PA; Han, X; Jones, HM; Schuler, KM; Sheng, X; Suri, A; Zhong, Y; Zhou, C, 2016) |
| "The present study was designed to investigate the effects of cyclooxygenase (COX) inhibitors in combination with taxol on the expression of cyclin D1 and Ki-67 in human ovarian SKOV-3 carcinoma cells xenograft-bearing mice." | 1.38 | Effects of cyclooxygenase inhibitors in combination with taxol on expression of cyclin D1 and Ki-67 in a xenograft model of ovarian carcinoma. ( Cai, JH; Li, W; Tang, YX; Wan, L; Zhang, J, 2012) |
| "The present study was designed to investigate whether taxol in combination with cyclooxygenase (COX) inhibitors could be superior on inhibitory effect of ovarian cancer growth than taxol alone as drug therapy of mice implanted with human ovarian carcinoma cell line SKOV-3." | 1.38 | Antitumor properties of taxol in combination with cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian tumor growth in vivo. ( Cai, J; Li, W; Liu, M; Tang, Y; Zhai, L; Zhang, J, 2012) |
| "MDSCs migrated toward ovarian cancer ascites in a CXCR4-dependent manner that required COX2 activity and autocrine PGE(2) production." | 1.37 | PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. ( Edwards, RP; Kalinski, P; Muthuswamy, R; Obermajer, N; Odunsi, K, 2011) |
| " We demonstrate that a reduction of cyclooxygenase 2 gene dosage rescued the ovarian aging phenotype of the Wv mice, whereas homozygous deletion was accompanied by a compensatory increase in ovarian cyclooxygenase 1 expression and prostaglandin E(2) synthesis." | 1.34 | A reduction of cyclooxygenase 2 gene dosage counters the ovarian morphological aging and tumor phenotype in Wv mice. ( Cai, KQ; Hamilton, TC; Klein-Szanto, A; Smedberg, JL; Smith, ER; Xu, XX; Yang, WL, 2007) |
| " Xenografted nude mice models of human ovarian cancer were established, and then randomly allocated to treatment or control group, which was administered with either Celecoxib at the dosage of 10, 25, 50 mg/kg or distilled water alone (control) orally daily for 56 d." | 1.34 | [The growth inhibitory effect of non-steroid anti-inflammatory drugs on ovarian cancer]. ( Liu, XQ; Lou, JY; Luo, FM; Peng, ZL; Wang, HJ; Yang, KX, 2007) |
| "The Celecoxib was more potential effects than Aspirin." | 1.33 | [Effects of nonsteroidal anti-inflammatory drug celecoxib on expression of cyclooxygenase-2 (COX-2) in ovarian carcinoma cell]. ( Liu, XJ; Lou, JY; Luo, FM; Peng, ZL; Wang, HJ; Yang, KX, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (34.62) | 29.6817 |
| 2010's | 17 (65.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, X | 1 |
| Yan, K | 1 |
| Deng, L | 1 |
| Liang, J | 1 |
| Liang, H | 1 |
| Feng, D | 1 |
| Ling, B | 1 |
| Hennequart, M | 1 |
| Pilotte, L | 1 |
| Cane, S | 1 |
| Hoffmann, D | 1 |
| Stroobant, V | 1 |
| Plaen, E | 1 |
| Van den Eynde, BJ | 1 |
| Wang, YP | 1 |
| Wang, QY | 1 |
| Li, CH | 1 |
| Li, XW | 1 |
| Shao, Z | 1 |
| Wen, Q | 1 |
| Zhu, T | 1 |
| Jiang, W | 1 |
| Kang, Y | 1 |
| Xu, C | 1 |
| Wang, S | 1 |
| Gupta, R | 1 |
| Cristea, M | 1 |
| Frankel, P | 1 |
| Ruel, C | 1 |
| Chen, C | 1 |
| Wang, Y | 1 |
| Morgan, R | 1 |
| Leong, L | 1 |
| Chow, W | 1 |
| Koczywas, M | 1 |
| Koehler, S | 1 |
| Lim, D | 1 |
| Luu, T | 1 |
| Martel, C | 1 |
| McNamara, M | 1 |
| Somlo, G | 1 |
| Twardowski, P | 1 |
| Yen, Y | 1 |
| Idorenyi, A | 1 |
| Raechelle, T | 1 |
| Carroll, M | 1 |
| Chung, V | 1 |
| Liu, R | 1 |
| Zheng, J | 1 |
| Li, C | 1 |
| Pang, Y | 1 |
| Zheng, Q | 1 |
| Xu, X | 1 |
| Liu, P | 1 |
| Thill, M | 1 |
| Woeste, A | 1 |
| Reichert, K | 1 |
| Fischer, D | 1 |
| Rody, A | 1 |
| Friedrich, M | 1 |
| Köster, F | 1 |
| van Kruchten, M | 1 |
| van der Marel, P | 1 |
| de Munck, L | 2 |
| Hollema, H | 2 |
| Arts, H | 1 |
| Timmer-Bosscha, H | 1 |
| de Vries, E | 1 |
| Hospers, G | 1 |
| Reyners, A | 1 |
| Webb, T | 1 |
| Carter, J | 1 |
| Roberts, JL | 1 |
| Poklepovic, A | 1 |
| McGuire, WP | 1 |
| Booth, L | 1 |
| Dent, P | 1 |
| Suri, A | 1 |
| Sheng, X | 1 |
| Schuler, KM | 1 |
| Zhong, Y | 1 |
| Han, X | 1 |
| Jones, HM | 1 |
| Gehrig, PA | 1 |
| Zhou, C | 1 |
| Bae-Jump, VL | 1 |
| Li, W | 4 |
| Jiang, HR | 2 |
| Xu, XL | 2 |
| Wang, J | 2 |
| Zhang, J | 4 |
| Liu, ML | 2 |
| Zhai, LY | 2 |
| Legge, F | 1 |
| Paglia, A | 1 |
| D'Asta, M | 1 |
| Fuoco, G | 1 |
| Scambia, G | 1 |
| Ferrandina, G | 1 |
| Obermajer, N | 1 |
| Muthuswamy, R | 1 |
| Odunsi, K | 1 |
| Edwards, RP | 1 |
| Kalinski, P | 1 |
| Reyners, AKL | 1 |
| Erdkamp, FLG | 1 |
| Smit, WM | 1 |
| Hoekman, K | 1 |
| Lalisang, RI | 1 |
| de Graaf, H | 1 |
| Wymenga, ANM | 1 |
| Polee, M | 1 |
| van Vugt, MATM | 1 |
| Schaapveld, M | 1 |
| Willemse, PHB | 1 |
| Cai, JH | 1 |
| Tang, YX | 1 |
| Wan, L | 1 |
| Zhai, L | 1 |
| Tang, Y | 1 |
| Cai, J | 1 |
| Liu, M | 1 |
| Barnes, MN | 1 |
| Chhieng, DF | 1 |
| Dreher, M | 1 |
| Jones, JL | 1 |
| Grizzle, WE | 2 |
| Jones, L | 1 |
| Talley, L | 1 |
| Partridge, EE | 1 |
| Vital-Reyes, V | 1 |
| Rodríguez-Burford, C | 1 |
| Chhieng, DC | 1 |
| Oelschlager, DK | 1 |
| Reyes-Fuentes, A | 1 |
| Barnes, M | 1 |
| Wang, HJ | 2 |
| Liu, XJ | 1 |
| Yang, KX | 2 |
| Luo, FM | 2 |
| Lou, JY | 2 |
| Peng, ZL | 2 |
| Yang, WL | 1 |
| Cai, KQ | 1 |
| Smedberg, JL | 1 |
| Smith, ER | 1 |
| Klein-Szanto, A | 1 |
| Hamilton, TC | 1 |
| Xu, XX | 1 |
| Song, YC | 1 |
| Kim, SH | 1 |
| Juhnn, YS | 1 |
| Song, YS | 1 |
| Liu, XQ | 1 |
| Sugimoto, T | 1 |
| Bartholomeusz, C | 1 |
| Tari, AM | 1 |
| Ueno, NT | 1 |
| Kanwar, VS | 1 |
| Heath, J | 1 |
| Krasner, CN | 1 |
| Pearce, JM | 1 |
| Bijman, MN | 1 |
| Hermelink, CA | 1 |
| van Berkel, MP | 1 |
| Laan, AC | 1 |
| Janmaat, ML | 1 |
| Peters, GJ | 1 |
| Boven, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Influence of the Celecoxib Administration Before Surgery for Endometrial Cancer on Indoleamine 2,3-dioxygenase 1 (IDO1) Tumor Expression and Immune Cells Tumor's Infiltration[NCT03896113] | Phase 2 | 48 participants (Anticipated) | Interventional | 2019-11-13 | Recruiting | ||
| Phase II Study of the Combination Carboplatin Plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients[NCT01124435] | Phase 2 | 45 participants (Actual) | Interventional | 2003-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for celecoxib and Cancer of Ovary
| Article | Year |
|---|---|
Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents | 2019 |
Hormone receptors as a marker of poor survival in epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2015 |
Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cel | 2011 |
A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the Do
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2012 |
Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: initial examination of celecoxib as a chemopreventive agent.
Topics: Adult; Anticarcinogenic Agents; Celecoxib; Cyclooxygenase Inhibitors; Female; Genetic Predisposition | 2005 |
21 other studies available for celecoxib and Cancer of Ovary
| Article | Year |
|---|---|
Cyclooxygenase 2 Promotes Proliferation and Invasion in Ovarian Cancer Cells via the PGE2/NF-κB Pathway.
Topics: Animals; Antineoplastic Agents; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell | 2019 |
Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance.
Topics: Animals; CD8-Positive T-Lymphocytes; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Dinoprostone; Fe | 2017 |
COX-2 inhibition by celecoxib in epithelial ovarian cancer attenuates E-cadherin suppression through reduced Snail nuclear translocation.
Topics: Blotting, Western; Cadherins; Carcinoma, Ovarian Epithelial; Celecoxib; Cell Line, Tumor; Cyclooxyge | 2018 |
Preventative effect of celecoxib in dimethylbenz[a]anthracene-induced ovarian cancer in rats.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenocarcinoma; Animals; Apoptosis; Carcinosarcoma; Celecoxib; Cel | 2018 |
Celecoxib induces epithelial-mesenchymal transition in epithelial ovarian cancer cells via regulating ZEB1 expression.
Topics: Cadherins; Carcinoma, Ovarian Epithelial; Celecoxib; Cell Line, Tumor; Cell Proliferation; Down-Regu | 2015 |
Vitamin D inhibits ovarian cancer cell line proliferation in combination with celecoxib and suppresses cyclooxygenase-2 expression.
Topics: Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Female; Humans; Ovarian Neoplasms | 2015 |
Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance.
Topics: Antineoplastic Agents; Carboplatin; Celecoxib; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resi | 2015 |
The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer.
Topics: Animals; Apoptosis; BRCA1 Protein; Celecoxib; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Prol | 2016 |
Cyclin D1 expression and the inhibitory effect of celecoxib on ovarian tumor growth in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclin D | 2010 |
Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian carcinoma in vivo.
Topics: Animals; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase | 2011 |
PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment.
Topics: Biphenyl Compounds; CD11b Antigen; Celecoxib; Cell Movement; Cells, Cultured; Chemokine CXCL12; Cycl | 2011 |
Effects of cyclooxygenase inhibitors in combination with taxol on expression of cyclin D1 and Ki-67 in a xenograft model of ovarian carcinoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2012 |
Antitumor properties of taxol in combination with cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian tumor growth in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2012 |
Celecoxib inhibits cellular growth, decreases Ki-67 expression and modifies apoptosis in ovarian cancer cell lines.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Caspase 3; Celecoxib; Cell Growth Processes; Cel | 2006 |
[Effects of nonsteroidal anti-inflammatory drug celecoxib on expression of cyclooxygenase-2 (COX-2) in ovarian carcinoma cell].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cys | 2006 |
A reduction of cyclooxygenase 2 gene dosage counters the ovarian morphological aging and tumor phenotype in Wv mice.
Topics: Adenoma; Aging; Animals; Blotting, Western; Celecoxib; Cell Transformation, Neoplastic; Cyclooxygena | 2007 |
Apoptotic effect of celecoxib dependent upon p53 status in human ovarian cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Celecoxib; Cell Line, Tumor; Female; Growth Inhibitors; Humans; Ne | 2007 |
[The growth inhibitory effect of non-steroid anti-inflammatory drugs on ovarian cancer].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Celecoxib; Cell Line, Tumor; C | 2007 |
Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells.
Topics: Adenovirus E1A Proteins; Apoptosis; Blotting, Western; Breast Neoplasms; Celecoxib; Cell Survival; C | 2007 |
Advanced small cell carcinoma of the ovary in a seventeen-year-old female, successfully treated with surgery and multi-agent chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Carcinoma, Small | 2008 |
Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels.
Topics: Antineoplastic Agents; Apoptosis; Celecoxib; Cell Division; Cell Line, Tumor; Cisplatin; Colonic Neo | 2008 |